What EV Biotech does

EV Biotech B.V. is a Dutch microbial cell factory company founded in 2018 and headquartered in Groningen, Netherlands, that engineers microbes to produce chemicals and proteins as sustainable alternatives to petrochemical-derived inputs. The company serves industrial partners pursuing precision fermentation, sustainable ingredient production, and industrial-scale biomanufacturing, addressing pain points around long development timelines, high R&D costs, scale-up failure rates, and dependence on food-grade carbon sources.

EV Biotech's core technology is the proprietary ArtemisAI platform, which combines artificial metabolic networks (AMNs), machine learning, and constraint-based modeling to construct explainable digital twins of microbial cells and fermentation processes. The platform enables in silico prototyping of thousands of gene and pathway combinations, multi-scale modeling from microliter reactors to industrial fermenters, media and side-stream optimization for low-cost carbon sources, and computational fluid dynamics-based scale-down fermentation simulation. The company offers two service lines built on this platform: Strain Development (greenfield strain creation from compound selection through proof of concept) and Strain Optimization (yield improvement, scale-up support, and media optimization for existing strains).

The company operates a partnership-based co-development model rather than a transactional SaaS or pure fee-for-service business. Revenue streams include professional services fees from strain development and optimization engagements, alongside longer-tail participation through royalties, licensing arrangements, and joint ventures tied to partner product success. Pricing is not publicly disclosed; engagements are modular and governed by Master Service Agreements. EV Biotech secured a €4.5 million seed round in March 2023 led by Future Food Fund and RUG Ventures, with participation from Blue Horizon Corporation, Carduso Capital, NV NOM, Triade Investment, and Voyagers, and operates with 11–50 employees across combined offices and laboratory facilities at the Zernike Campus in Groningen.

Name

EV Biotech

Legal name

EV Biotech B.V.

Website

https://evbio.tech

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

EV Biotech B.V. is a Dutch precision fermentation company that uses its proprietary ArtemisAI platform — combining artificial metabolic networks, machine learning, and constraint-based modeling — to co-design, optimize, and scale microbial production strains with industrial partners seeking sustainable, bio-based chemical and protein alternatives to petrochemical inputs.

Ownership category

akta.pro rank

Product category

Industrial Biotechnology / Precision Fermentation Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Industrial Organic Chemicals (2860)

akta.pro primary industry

Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids) (EUAAAIAL)

akta.pro secondary industries

Formulation R&D, Scale-Up & Tech Transfer Services (AFABAIAJ), Biologicals Formulation & Fermentation Tolling (microbials, bio-stimulants) (AFABAIAC)

Keywords

• Precision fermentation
• Microbial strain engineering
• AI metabolic modeling
• Bio-based chemicals
• Industrial biotechnology

Headquarters

HQ city

Groningen

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Royalties and Licensing: EV Biotech shares in partner success through royalties, licensing arrangements, or joint ventures as part of their co-development model.
2. Contract Research Services: Fee-for-service engagement on strain development and optimization projects, where EV Biotech assists at each stage from compound selection to scale-up assistance.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

EV Biotech designs, engineers, and optimizes microbial production strains for the precision fermentation industry using its proprietary ArtemisAI platform. The company partners with industrial clients on co-development projects covering the full lifecycle from early strain engineering and metabolic pathway design through laboratory validation to industrial-scale readiness. Revenue is generated via contract research services, royalties, licensing arrangements, and joint ventures on developed products.

Product overview

EV Biotech operates as a co-development partner offering a unified platform-and-services model centered on their proprietary ArtemisAI technology. ArtemisAI serves as the core AI engine that combines metabolic modeling, machine learning, and constraint-based approaches to design and optimize microbial production strains. The company offers two complementary service lines: Strain Development for creating new production strains from scratch (covering compound selection, host organism identification, proof of concept, and initial optimization), and Strain Optimisation for enhancing existing strains and processes (including yield improvements, scale-up support, and media optimization). All offerings follow a co-development model with shared upside through royalties, licenses, or joint ventures.

Differentiator

Problem solved

Functional benefit

Brands

• ArtemisAI: Proprietary predictive platform combining artificial metabolic networks (AMNs), machine learning, and constraint-based modeling to design and optimize microbial production strains.

Products and services

• ArtemisAI Platform Proprietary AI platform combining artificial metabolic networks (AMNs), machine learning, and constraint-based modeling to design, simulate, and optimize microbial production strains. Creates digital twins of microbial cells and fermentation processes for predictive strain development, in silico prototyping, multi-scale modeling, and media optimization. Used as the foundational technology for EV Biotech's co-development service offerings to industrial partners.
• Strain Development End-to-end co-development service for creating new microbial production strains, targeted at companies with strategic ambitions for precision fermentation that want to start with a new product or process. Covers compound selection, metabolic pathway search, IP landscape analysis, genome-scale metabolic modeling, and laboratory testing at lab scale, leading to a proof-of-concept production strain.
• Strain Optimisation Modular optimization service for improving existing production strains and processes, targeted at companies with a working strain or process that want to optimize performance. Includes yield enhancement, industrial scale-up support, and media optimization using synergistic cycles of modeling and experimentation, including leveraging side streams and low-cost carbon sources.

Quantifiable outcome

• Drastically reduces number of wet lab iterations needed through in silico strain prototyping
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Six partnerships are on record, tiered minor.

• Prof. dr. Ben FeringaminorOthersNobel Laureate in Chemistry 2016 who has publicly endorsed EV Biotech's bacterial engineering technology for sustainable chemical products, stating he will follow the company closely.
• Dr. Ton VriesminorOthersManaging Director of MercachemSyncom and Groningen Campus who has endorsed EV Biotech's alternative technologies for chemical production using bacterial engineering, expressing positivity about the technology and its potential.
• Prof. dr. Aard GroenminorOthersProfessor of Entrepreneurship at the University of Groningen who has endorsed EV Biotech's development from EIT-health Venturelab program graduate to a competent entrepreneurial team ready for the high-tech biotechnology field.
• University of GroningenminorStrategic or Co-development PartnerAcademic partner providing access to research expertise and talent pipeline. EV Biotech has connections to the university through founders and advisors, with endorsement from professors.
• SNN (Samenwerkingsverband Noord-Nederland)minorStrategic or Co-development PartnerRegional development agency for Northern Netherlands that supports innovative companies in the region, listed as a trusted partner on EV Biotech's website.
• Holland BiominorStrategic or Co-development PartnerDutch biotech industry association providing networking, advocacy, and industry representation for Dutch biotechnology companies.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Conagen: Conagen is a synthetic biology company that develops engineered microorganisms for production of ingredients, flavors, fragrances, and chemicals through precision fermentation. It directly competes with EV Biotech in microbial strain development for sustainable chemical production.
• LabGenius: LabGenius is a UK-based AI-driven protein engineering company that combines machine learning with robotic lab automation to design novel proteins. It is comparable to EV Biotech in using AI/ML for biological engineering, though focused on protein therapeutics rather than microbial production strains.
• Culture Biosciences: Culture Biosciences offers cloud-based fermentation services and bioprocess development for biotech companies. It is comparable to EV Biotech in serving strain development and optimization needs, though Culture focuses on service delivery with proprietary bioreactor infrastructure rather than AI-driven strain design.
• Cradle: Cradle is an AI-powered protein and biology design platform that uses generative machine learning to engineer proteins and enzymes for industrial biotech applications. It is highly comparable to EV Biotech in combining AI/ML with biological design, though Cradle focuses primarily on proteins while EV Biotech focuses on whole-cell microbial systems.
• Bota Bio: Bota Bio is a synthetic biology company that develops microbial cell factories for sustainable production of chemicals and materials using AI-driven strain engineering. It directly competes with EV Biotech in the precision fermentation co-development space targeting bio-based chemical production.
• Inscripta (now Infinite Worlds): Inscripta developed a digital genome engineering platform combining CRISPR-based tools with software for microbial strain development. It is comparable to EV Biotech in integrating computational tools with biological engineering for industrial applications.

Emerging players

• bit.bio: bit.bio is a synthetic biology company that develops iPSC-derived human cells using its proprietary cell编程 technology for research and therapeutic applications. It is partially comparable to EV Biotech in combining AI/ML with cell engineering, though focused on mammalian cell systems rather than microbial production strains.
• TeselaGen: TeselaGen provides an AI-enabled platform for DNA design and organism engineering with lab automation capabilities for biotech R&D. It is comparable to EV Biotech in providing software-driven tools for biological design, though it offers general synthetic biology tooling rather than focused microbial production strain development.

Broad incumbents

• Ginkgo Bioworks: Ginkgo Bioworks is a well-funded cell engineering platform that designs custom microorganisms for industrial applications across food, pharma, and chemicals. It directly competes with EV Biotech in providing AI-enabled strain design and fermentation optimization, though at much larger scale and broader scope.
• Amyris: Amyris is an established synthetic biology company that engineers yeast strains for sustainable production of ingredients and chemicals at industrial scale. It overlaps with EV Biotech in precision fermentation for bio-based chemicals but operates at much larger commercial scale with its own ingredient product lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/evbiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EV Biotech